Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 11, 2002, Pages 1337-1348

  Kottke Marchant, Kandice ^a   Comp, Philip ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C; PROTEIN C RECEPTOR; RECEPTOR; THROMBOMODULIN; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DIAGNOSTIC TEST; GENETIC DISORDER; HUMAN; LABORATORY DIAGNOSIS; MEDICAL LITERATURE; MEDICAL SOCIETY; PATHOLOGIST; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK FACTOR; THROMBOPHILIA;

BLOOD COAGULATION FACTORS; HUMANS; PRACTICE GUIDELINES; PROTEIN C; PROTEIN C DEFICIENCY; RECEPTORS, CELL SURFACE; RISK FACTORS; THROMBOMODULIN; THROMBOPHILIA; THROMBOSIS;

EID: 0036881537     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (153)

1. Kisel W. Human plasma protein C: isolation, characterization and activation by human thrombin. J Clin Invest. 1979;64:761-769.
2. Marlar RA, Kleiss AJ, Griffin J. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 1982;59:1067-1072.
3. Mammen EF, Thomas WR, Seegers WH. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II) or autoprothrombin II-A. Thromb Diath Haemorrh. 1960;5:218-250.
4. Stenflo J. A new vitamin K-dependent protein: purification from bovine plasma and preliminary characterization. J Biol Chem. 1976;251:355-363.
5. Esmon CT, Protein C, protein S and thrombomodulin. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:335-353.
6. D'Angelo SV, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest. 1986;77:416-425.
7. Greenberg DL, Davie EW. Blood coagulation factors: their complementary DNAs, genes, and expression. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:21-58.
8. Fernlund P, Stenflo J. Amino acid sequence of the light chain of bovine protein C. J Biol Chem. 1982;257:12170-12179.
9. Stenflo J, Fernlund P. Amino acid sequence of the heavy chain of bovine protein C. J Biol Chem. 1982;247:12180-12190.
10. Grinnell BW, Walls JD, Gerlitz B, et al. Native and modified recombinant human protein C: function, secretion, and posttranslational modifications. In: Bruley DF, Drohan WN, eds. Protein C and Related Anticoagulants. Houston, Tex: Gulf Publishing Co; 1991:29-63. Advances in Applied Biotechnology Series; vol 11.
11. Foster D, Davie EW. Characterization of a cDNA coding for human protein C. Proc Natl Acad Sci U S A. 1984;81:4766-4770.
12. Long TL, Belagaje RM, MacGillivray RTA. Coding and sequencing of liver cDNA coding for bovine protein C. Proc Natl Acad Sci U S A. 1984;81:4766.
13. Drakenberg T, Fernlund P, Roepstorff P, Stenflo J. Beta-hydroxy-aspartic acid in vitamin K - dependent protein C. Proc Natl Acad Sci U S A. 1983;80: 1802-1806.
14. Kato A, Miura O, Sumi Y, Aoki N. Assignment of the human protein C gene to chromosome region 2q14:q21 by in situ hybridization. Cytogenet Cell Genet. 1988;47:46-47.
15. Patracchini P, Aello V, Palazzi P, Calzolari E, Bernardi F. Sublocalization of the human protein C gene on chromosome 2q13-q14. Hum Genet. 1989;81: 191-192.
16. Plutzky J, Hoskins JA, Long GL, Crabtree GR. Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A. 1986;83:546-550.
17. Reitsma PH, Bernardi F, Doig RG, et al, for the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Protein C deficiency: a database of mutations, 1995. Thromb Haemost. 1995;73:876-889.
18. Miao Ch, Ho WT, Greenberg DL, Davie EW. Transcriptional regulation of the gene coding for human protein C. J Biol Chem. 1996;271:9587-9594.
19. Castellini FJ. Human protein C and activated protein C. Trends Cardiovasc Med. 1996;5:55-62.
20. Sadler JE, Lentz SR, Sheehan JP, Tsiang M, Wu Q. Structure-function relationships of the thrombin-thrombomodulin interaction. Haemostasis. 1993;23: 183-193.
21. Ye J, Esmon NL, Esmon CT, Johnson AE. The active site of thrombin is altered upon binding to thrombomodulin: two distinct structural changes are detected by fluorescence, but only one correlates with protein C activation. J Biol Chem. 1991;266:23016-23021.
22. Fukodome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269: 26486-26491.
23. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood. 2001;97:1685-1688.
24. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998;101:1983-1991.
25. Stocker K, Fischer H, Meier J, Brogli M, Svendsen L. Protein C activators in snake venoms. Behring Inst Mitt. 1986;79:37-47.
26. Klein JD, Walker FJ. Purification of a protein C activator from the venom of the southern copperhead snake (Agkistrodon contortrix contortrix). Biochemistry. 1986;25:4175-4179.
27. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascade through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603-16608.
28. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation intovesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem. 1994;269:816-819.
29. Zhang L, Jhingan A, Castellino FJ. Role of individual gamma-carboxyglutamic acid residue of activated human protein C in defining its in vitro anticoagulant activity. Blood. 1992;80:942-952.
30. Zhang L, Castellin FJ. The binding energy of human coagulation protein C to acidic phospholipid vesicles contains a major contribution from leucine 5 in the gamma-carboxyglutamic acid domain. J Biol Chem. 1994;269:3590-3595.
31. Harris KW, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem. 1985;260:2007-2010.
32. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269: 31869-31880.
33. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor Villa. J Biol Chem. 1991;266:20139-20145.
34. Pellequer JL, Gale AJ, Getzhoff ED, Griffin JH. Three dimensional model of coagulation factor Va bound to activated protein C. Thromb Haemost. 2000; 84:849-857.
35. Egan JO, Kalafatis M, Mann KG. The effect of Arg306-Ala and Arg506-Gn substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci. 1997;6:2016-2027.
36. Mann KG, Hockin MF, Begin KJ, Kalafatis M. Activated protein C cleavage of factor Va leads to dissociation of the A2 domaim. J Biol Chem. 1997;272: 20678-20683.
37. Amano K, Michnick DA, Moussalli M, Kaufman RJ. Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: implications for the APC resistance test. Thromb Haemost. 1998;79:557-563.
38. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994;269:18735-18738.
39. Scully MF, Toh CH, Hoogendoorn H, et al. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α1-antitrypsin and α2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost. 1993;69:448-453.
40. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-1373.
41. Spek CA, Greengard JS, Griffin JH, Bertina RM, Reitsma PH. Two mutations in the promoter region of the human protein C gene: both cause type I protein C deficiency by disruption of two HNF-3 binding sites. J Biol Chem. 1995;270: 24216-24221.
42. Marder VJ, Matei DE. Hereditary and acquired thrombophilic syndromes. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1243-1275.
43. Broekmans AW, Bertina RM, Loelinger EA, et al. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost. 1983; 49:251.
44. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood. 1989;73:712-717.
45. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet. 1993;341:134-138.
46. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism: a study of three Dutch families. N Engl J Med. 1983a;309:340-344.
47. Henkins CMA, Van der Meer J, Hillege JL, Van der Schaaf W, Bom VJJ, Halie MR. The clinical expression of hereditary protein C and protein S deficiency: a relation to clinical thrombotic risk factors and to levels of protein C and protein S? Blood Coagul Fibrinolysis. 1993;4:555-562.
48. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987;317:991-996.
49. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell. 1993;72:477-480.
50. Koeleman BPC, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol. 1997;34:256-264.
51. Bettina RM. An international collaborative study on the performance of protein C antigen assays. Thromb Haemost. 1987;57:112-117.
52. Pabinger I, Mustafa S, Rintelen C, et al. Factor V (FV) Leiden mutation (APC-resistance) increases the risk for venous thromboembolism in patients with a gene defect of the protein C (PC) or protein S (PS) gene [abstract]. Thromb Haemost. 1995;72:1361.
53. Brenner B, Zivelin A, Lanir N, et al. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Blood. 1996;88:877-880.
54. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031-1035.
55. Simoni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81:198-202.
56. Bovill EG, Hasstedt SJ, Callas PW, et al. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in large protein C deficient kindred. Thromb Haemost. 2000;83:366-370.
57. Bovill EG, Hasstedt SJ, Leppert MF, Long GL. Hereditary thrombophilia as a model for multigenic disease. Thromb Haemost. 1999;82:662-666.
58. Camerlingo M, Finazzi G, Casto L, et al. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology. 1991;41:1371-1373.
59. Sakata T, Kario K, Katayama Y, et al. Analysis of 45 episodes of arterial occlusive disease in Japanese patients with congenital protein C deficiency. Thromb Res. 1999;94:69-78.
60. Broekmans AW, Conard J. Hereditary protein C deficiency. In: Bertina RM, ed. Protein C and Related Proteins. Edinburgh, Scotland: Churchill Livingstone; 1988:160-181.
61. McGehee WG, Klotz TA, Epstein DJ, Rapaport SI: Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med. 1984;101:59-60.
62. Weiss P, Soff GA, Halkin H, Seligsohn U. Decline of protein C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res Suppl. 1987;45:783-790.
63. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J, and the EMET group. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism: results of the Spanish Multicentric Study on Thrombophilia (EMET Study). Thromb Haemost. 1997;77:444-451.
64. Briet E, Engesser L, Brommer EJP, Broekmans AW, Bertina RM. Thrombophilia: its causes and a rough estimate of its prevalence [abstract]. Thromb Haemost. 1987;58:39.
65. Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost. 1988;59:18-22.
66. Engesser L, Brommer EJP, Kluft C, Briet E. Elevated plasminogen activator inhibit (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic thrombophilia. Thromb Haemost. 1989;62:673-680.
67. Scharrer I, Hach-Wunderle V, Heyland H, Kuhn C. Incidence of defective tPA release in 158 unrelated young patients with venous thrombosis in comparison to PC-, PS-, ATIII-, fibrinogen-, and plasminogen deficiency. Thromb Haemost. 1987;58:72.
68. Ben Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost. 1989;61:50-54.
69. Bick RL, Jakway J, Baker WF. Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost. 1992;18:267-274.
70. Taberno MD, Tomia JF, Alberea I, Orfao A, Lopez-Borrasca A, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991;36:249-254.
71. Melissari E, Monte G, Lindo VS, et al. Congenital thrombophilia among patients with venous thromboembolism. Blood Coagul Fibrinolysis. 1992;3:749-758.
72. Malm J, Laurell M, Nilsson IM, Dahlback B. Thromboembolic disease: critical evaluation of laboratory investigation. Thromb Haemost. 1992;68:7-13.
73. Pabinger I, Brucker S, Kyrle PA, et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis. 1992; 3:547-553.
74. Suehisa E, Nomura T, Kawasaki T, Kanakura Y. Frequency of natural coagulation inhibitor (antithrombin III, protein C and protein S) deficiencies in Japanese patients with spontaneous deep vein thrombosis. Blood Coagul Fibrinolysis. 2001;12:95-99.
75. Heijboer H, Brandjes DPM, Buller HR, Sturk A, ten Cate LW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1516.
76. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-2761.
77. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995;73:87-93.
78. Pabinger I, Kyrle PA, Heistinger M, et al. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost. 1994;71:441-445.
79. Marlar RA, Montgomery RR, Broekmans AW, and the Working Party. Diagnosis and treatment of homozygous protein C deficiency: report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr. 1989;114:528-534.
80. Sills RH, Marlar RA, Montgomery RR, Deshphande GN, Humbert JR. Severe homozygous protein C deficiency. J Pediatr. 1984;105:409-413.
81. Estelles A, Garcia-Plaza I, Dasi A, et al. Severe inherited "homozygous" protein C deficiency in a newborn infant. Thromb Haemost. 1984;52:53-56.
82. Marciniak E, Wilson HD, Marlar RA. Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood. 1985;65:15-20.
83. Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive thrombosis in the newborn. N Engl J Med. 1984;310:559-562.
84. Branson HE, Marble R, Katz J, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983;2:1165-1168.
85. Marlar RA. Protein C in thromboembolic disease. Semin Thromb Hemost. 1985;11:387-393.
86. Pabinger I, Kyrle PA, Speiser W, Stoffels U, Jung M, Lechner K. Diagnosis of protein C deficiency in patients on oral anticoagulant treatment: comparison of three different functional protein C assays. Thromb Haemost. 1990;63:407-412.
87. Triplett DA, Sandquist DS, Musgrave KA. Clinical application of a functional assay for protein C. Hematol Pathol. 1987;1:239-247.
88. Rodeghiero F, Mannucci PM, Vigano S, et al. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood. 1984;63:965-969.
89. Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood. 1985b;66:59-63.
90. Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet. 1982;2:463-467.
91. Mannucci PM, D'Angelo A, Vigano S, et al. Decrease and rapid recovery of protein C after plasma exchange. Transfusion. 1986;26:156-158.
92. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 1989;63:1303-1307.
93. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
94. Cosio FG, Harker C, Batard MA, et al. Plasma concentration of the natural anticoagulants protein C and protein S in patients with proteinurea. J Lab Clin Med. 1985;106:218-222.
95. Sorensen PJ, Knudsen F, Nielsen AH, Dyerberg J. Protein C activity in renal disease. Thromb Res. 1985;38:243-249.
96. Mitchell CA, Rowell JA, Hau L, et al. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med. 1987;317:1638-1642.
97. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full term infant. Blood. 1987;70:165-172.
98. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.
99. Vigano S, Mannucci PM, D'Angelo A, et al. Protein C is not an acute phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost. 1984;52:263-266.
100. Mannucci PM, Vigano S, Bottassco B, et al. Protein C antigen during pregnancy, delivery and puerperium. Thromb Haemost. 1984;52:217.
101. Meade TW, Stirling Y, Wilkes H, Mannucci PM. Effects of oral contraceptives and obesity on protein C antigen. Thromb Haemost. 1985;53:198-199.
102. Ohlin AK, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost. 1997;78:396-400.
103. Norlund L, Holm J, Zoller B, Ohlin AK. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost. 1997;77:248-251.
104. van der Velden PA, Krommenhoek-Van Es T, Allaart CF, Bertina RM, Reitsma PH. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia. Thromb Haemost. 1991;65:511-513.
105. Le Flem L, Picard V, Emmerich J, et al. Mutations in promoter region of thrombomodulin and venous thromboembolic disease. Arterioscler Thromb Vasc Biol. 1999;19;1098-1104.
106. Weiler H, Lindner V, Kerlin B, et al. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol. 2001;21:1531-1537.
107. Fukudome K, Esmon DT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994a;269: 26486-26491.
108. Merat G, Biguzzi F, Oganesyan N, et al. A 23bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep venous thrombosis [abstract]. Thromb Haemost. 1999;(suppl):507.
109. Biguzzi E, Merati G, Liaw PC, et al. A 23bp insertion in the endothelial cell protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost. 2001;86:945-948.
110. Amiral J. Assay of protein C by an immuno-enzymatic method (ELISA). Am Clin Prod Rev. 1984;3:34-35.
111. Boyer C, Rothschild C, Wolf M, et al. A new method for the estimation of protein C by ELISA. Thromb Haemost. 1984;36:579-589.
112. Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest. 1977;29:21-32.
113. Ikeda K, Stenflo J. A radioimmunoassay for protein C. Thromb Res. 1985; 39:297-306.
114. Marlar RA, Adcock DM. Clinical evaluation of protein C: a comparative review of antigenic and functional assays. Hum Pathol. 1989b;20:1040-1047.
115. Bertina RM. An international collaborative study on the performance of protein C antigen assays. Thromb Haemost. 1987;57:112-117.
116. Mannucci PM, Boyer C, Tripodi A, et al. Multicenter comparison of five functional and two immunological assays for protein C. Thromb Haemost. 1987; 57:44-48.
117. Comprehensive Coagulation, College of American Pathologists Proficiency Survey (CG2-C). Northfield, III: College of American Pathologists; 2000.
118. Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost. 1982; 48:1-5.
119. Hubbard AR. Standardization of protein C in plasma: establishment of an international standard. Thromb Haemost. 1988;59:464-467.
120. Karpatkin M, Mannucci PM, Bhogal M, et al. Low protein C in the neonatal period. Br J Haematol. 1986;62:137-142.
121. Polack B, Pouzol P, Amiral J, Kolodie L. Protein C level at birth. Thromb Haemost. 1984;52:188-191.
122. Pabinger I, Allaart CF, Hermans J, et al. Hereditary protein C deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure: report on a study of the SSC Subcommittee on Protein C and Protein S. Thromb Haemost. 1992b;68:470-474.
123. Bauer K. The hypercoagulable state. In: Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis. 3rd ed. Philadelphia, Pa: Saunders; 1996:228-258.
124. Francis RB, Patch MJ. A functional assay for protein C in human plasma. Thromb Res. 1983;32:605-613.
125. Martinoli JL, Stocker K. Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res. 1986;43:253-264.
126. Espana F, Estelles A, Aznar J, Gilabert J. Assay of protein C in human plasma: comparison of amidolytic, coagulation and immunochemical assays. Thromb Res. 1986;44:771-782.
127. Guglielmone HA, Vides MA. A novel functional assay of protein C in human plasma and its comparison with amidolytic and anticoagulant assays. Thromb Haemost. 1992;67:46-49.
128. Francis RB, Seyfert U. Rapid amidolytic assay of protein C in whole plasma using an activator from the venom of Agkistrodon contortrix. Am J Clin Pathol. 1986;87:619-625.
129. Geiger M, White TM, Griffin JH. Functional assays for protein C activity and protein C inhibitor activity in plasma. Thromb Haemost. 1989;61:86-92.
130. Walker PA, Bauer KA, McDonagh J. A simple, automated functional assay for protein C. Am J Clin Pathol. 1989;92:210-213.
131. Richards SM, Olson T, Keyes LD. Quantitative and functional assays compared for determination of zymogen and activated human protein C. Clin Chem. 1990;36:1892-1896.
132. Marlar RA, Adcock DM, Madden RM. Hereditary dysfunctional protein C molecules (Type II): assay characterization and proposed classification. Thromb Haemost. 1990;63:375-379.
133. De Moerloose P, Reber G, Bouvier C. Spuriously low levels of protein C with Protac activation clotting assay. Thromb Haemost. 1988;59:543.
134. Francis RB. A simplified PTT-based protein C activity assay using thrombin-thrombomodulin complex. Thromb Res Suppl. 1986;41:337-344.
135. Vigano D'Angelo S, Comp PC, Esmon CT, et al. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest. 1986;77:416-425.
136. Han P, Fung KP, Rahdakrishnan U. Lack of agreement of chromogenic and clotting assays for factor X and protein C in warfarinised plasma. Thromb Haemost. 1991;65:360-363.
137. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2. Thromb Haemost. 1997;76:824-834.
138. Dahlback B, Cadsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
139. Krauss M, Noah M, Fichenscher K. The PCAT: a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res. 1995;79:217-222.
140. Robert A, Eschwege V, Hameg H, Drouet L, Aillaud MF. Anticoagulant response to Agkistrodon contortrix venom (ACV) test: a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost. 1996;75: 562-565.
141. Dati F, Hafner G, Erbes H, et al. Proc Global: the first functional screening assay for the complete protein C pathway. Clin Chemistry. 1997;43:1719-1723.
142. Haas FJLM, van Sterkenburg-Kamp BM, Scheepers HAMM. A protein C pathway (PCP) screening test for the detection of APC resistance and protein C or S deficiencies. Semin Thromb Hemost. 1998;24:355-362.
143. Neuwald C, Heinschink A, Muller MM. Evaluation of a new screening assay, protein C pathway (PCP) test, for identification of defects in the protein C pathway. Thromb Haemost. 1999;81:992-994.
144. Ruzicka K, Kapiotis S, Quehenberger P, et al. Evaluation of a new screening assay Proc Global for identification of defects in the protein C/protein S anticoagulation pathway. Thromb Res. 1997;87:501-510.
145. Toulon P, Perez P. Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathway. Hematol Oncol Clin North Am. 2000;14:379-389.
146. Toulon P, Halbmayer WM, Hafner G, et al. Screening for abnormalities of the protein C anticoagulant pathway using the Proc Global assay: results of a European multicenter evaluation. Blood Coagul Fibrinolysis. 2000;11:447-453.
147. Gemmati D, Serino ML, Scapoli GL. A modified functional global test to measure protein C, protein S activities and the activated protein C-resistance phenotype. Thromb Res. 1998;92:141-148.
148. Krauss M. The anticoagulant potential of the protein C system in hereditary and acquired thrombophilia: pathomechanisms and new tools for assessing its clinical relevance. Semin Thromb Hemost. 1998;24:337-354.
149. Haustein KO, Huller G. Pharmacokinetics of phenprocoumon. J Clin Pharmacol Ther. 1994;32:192-197.
150. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis: venous thromboembolism, myocardial infarction, stroke, and other conditions. Arch Pathol Lab Med. 2001;126:1281-1295.
151. Tans G, Cuivers J, Middledorp S, et al. A randomized cross-over study on the effects of levonorgestrel and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15-21.
152. Anderson BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost. 1998;79:28-31.
153. Bertina RM, Broekmans AW, Van es Krommenhoek C, Van Wijn Arden A. The use of functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost. 1984; 51:1-5.